About AAPP Toolkits
AAPP toolkits highlight both the evidence base available as well as strategies of clinical decision making used by expert psychiatric pharmacist clinicians. The content reflects the views and practice of the authors as substantiated with evidence-based facts as well as opinion and experience. Toolkits are peer reviewed by psychiatric pharmacists. Authors and AAPP review and update toolkits annually and strive to use up-to-date, non-stigmatizing language. Terminology does evolve rapidly and often regionally such that there may be differences between reader experiences and expectations and those of the author(s). AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
Phenibut (β-phenyl-γ-aminobutyric acid; also known as 4-amino-3-phenyl-butyric acid) is a synthetic GABA analog and central nervous system (CNS) depressant that was developed in the 1960s in the former Soviet Union. In the United States, phenibut has never been approved by the FDA for any medical indication but is widely available for purchase online, where it is misleadingly marketed. This toolkit includes:
- Pharmacology
- Epidemiology & Patterns of Use
- Clinical Presentation
- Diagnostic Approach
- Management of Acute Intoxication
- Management of Withdrawal
- Special Considerations
- Key Clinical Pearls
- Resources & Consultation
- References